GlucoTrack
GCTK
4 hedge funds and large institutions have $133K invested in GlucoTrack in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
120% more capital invested
Capital invested by funds: $60.2K → $133K (+$72.5K)
33% more funds holding
Funds holding: 3 → 4 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $65.5K | +$55.9K | +23 | New |
|
|
AF
2
Alerus Financial
Grand Forks,
North Dakota
| $33.4K | – | – | – |
|
3
Cetera Investment Advisers
Schaumburg,
Illinois
| $24.1K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $7.43K | -$4.86K | -2 | -40% |
|
5
Morgan Stanley
New York
| $1.21K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $1.04K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $75 | – | – | – |
|
GCTK Hedge Fund Activity: Q3 2024 in Review
4 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q3 2024, worth a combined $133K — up 120% from $60.2K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GCTK positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $55.9K. The largest seller was UBS Group, cutting an estimated $4.86K.
- 4 institutional investors held GlucoTrack (GCTK) as of Q3 2024, up from 3 in Q2 2024.
- Funds reported $133K of GlucoTrack stock for Q3 2024, up 120% quarter-over-quarter.
- 1 fund opened new GlucoTrack positions in Q3 2024 and 0 closed out, a net change of +1 holder.
- The largest GlucoTrack buyer in Q3 2024 was Geode Capital Management, an estimated $55.9K added.
- The largest GlucoTrack seller in Q3 2024 was UBS Group, an estimated $4.86K sold.
Based on aggregated 13F filings for Q3 2024.